The investigational MRI contrast agent, gadoquatrane, is designed to deliver effective imaging at a significantly reduced ...

Bayer BAYRY announced that it has submitted a new drug application (“NDA”) to the FDA seeking approval for its ...

The company's application included a submitted dose of 0.04 millimole gadolinium per kilogram of body weight. If approved, gadoquatrane would become the lowest dose macrocyclic gadolinium-based ...

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, after reviewing new data for the drug in metastatic ...

An experimental, non-hormonal drug from Bayer can reduce the hot flashes and other menopausal side effects many women taking a common breast cancer therapy experience, according to results from a late ...

Bayer meanwhile recently started a fourth phase 3 trial of elinzanetant that will test the drug's ability to treat VMS associated with endocrine therapy of breast cancer. GlobalData recently ...

The first successes of the turnaround are visible,' said Markus Manns, a portfolio manager at Union Investment in Frankfurt.

Bayer shares rise to eight-month highs after scoring analyst upgrades to Buy at both HSBC and Kepler Cheuvreux with ...

Bayer AG Innovation Procurement has signed a multi-year extension with Scientist.com, becoming Bayer’s preferred global ...

Berlin: Bayer has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ...

Bayer has taken another step toward achieving its €3 billion peak sales estimate for androgen receptor inhibitor Nubeqa, scoring an FDA approval to expand its use to all patients with metastatic ...